Trial Profile
A randomized, double-blind, placebo-controlled, multi-centre phase IIa study evaluating the safety and tolerability of IRL752 in patients with Parkinson's Disease Dementia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Mar 2020
Price :
$35
*
At a glance
- Drugs Pirepemat (Primary)
- Indications Dementia; Parkinson's disease
- Focus Adverse reactions; Proof of concept
- Sponsors Integrative Research Laboratories
- 12 Mar 2020 Results published in the Movement Disorders
- 23 Sep 2019 According to an Integrative Research Laboratories media release, results from this trial will be presented at the 2019 International Congress of Parkinson's Disease and Movement Disorders in Nice, France.
- 16 Nov 2018 Status changed from recruiting to completed.